Eterna Therapeutics (ERNA) Competitors $0.25 +0.00 (+1.05%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ERNA vs. GTBP, HOTH, CANF, ELAB, IMCC, BMRA, AEZS, PPBT, BNOX, and UPXIShould you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include GT Biopharma (GTBP), Hoth Therapeutics (HOTH), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), IM Cannabis (IMCC), Biomerica (BMRA), Aeterna Zentaris (AEZS), Purple Biotech (PPBT), Bionomics (BNOX), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Eterna Therapeutics vs. GT Biopharma Hoth Therapeutics Can-Fite BioPharma Elevai Labs IM Cannabis Biomerica Aeterna Zentaris Purple Biotech Bionomics Upexi GT Biopharma (NASDAQ:GTBP) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Does the media prefer GTBP or ERNA? In the previous week, GT Biopharma had 1 more articles in the media than Eterna Therapeutics. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for Eterna Therapeutics. GT Biopharma's average media sentiment score of 0.92 beat Eterna Therapeutics' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Positive Eterna Therapeutics Neutral Does the MarketBeat Community believe in GTBP or ERNA? GT Biopharma received 117 more outperform votes than Eterna Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformGT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% Eterna TherapeuticsN/AN/A Which has higher valuation and earnings, GTBP or ERNA? GT Biopharma has higher earnings, but lower revenue than Eterna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$7.60MN/AN/AEterna Therapeutics$598K2.26-$21.67M-$8.31-0.03 Which has more risk & volatility, GTBP or ERNA? GT Biopharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.18, suggesting that its stock price is 318% more volatile than the S&P 500. Do insiders & institutionals believe in GTBP or ERNA? 8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are owned by institutional investors. 10.9% of GT Biopharma shares are owned by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is GTBP or ERNA more profitable? GT Biopharma has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. GT Biopharma's return on equity of -257.47% beat Eterna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -257.47% -131.09% Eterna Therapeutics -7,513.88%-1,466.71%-117.48% Do analysts recommend GTBP or ERNA? GT Biopharma currently has a consensus price target of $11.00, indicating a potential upside of 530.37%. Given GT Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe GT Biopharma is more favorable than Eterna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Eterna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryGT Biopharma beats Eterna Therapeutics on 11 of the 15 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricEterna TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0310.5990.0517.18Price / Sales2.26196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.615.094.784.78Net Income-$21.67M$151.83M$120.31M$225.60M7 Day Performance-13.46%-2.14%-1.92%-1.23%1 Month Performance-51.90%-4.56%13.65%0.46%1 Year Performance-86.63%8.87%28.34%15.24% Eterna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAEterna TherapeuticsN/A$0.25+1.1%N/A-85.4%$1.35M$598,000.00-0.0310Gap DownHigh Trading VolumeGTBPGT Biopharma3.6544 of 5 stars$2.51-8.7%$11.00+338.2%-78.3%$5.61MN/A0.008Positive NewsGap UpHOTHHoth Therapeutics2.0095 of 5 stars$0.81flat$3.50+332.1%-30.8%$5.59MN/A-0.614Gap UpCANFCan-Fite BioPharma1.7922 of 5 stars$1.51-4.4%$14.00+827.2%-30.7%$5.35M$667,000.00-0.888ELABElevai Labs0.3441 of 5 stars$2.06-10.0%N/A-99.3%$5.33M$2.45M-0.0318News CoverageGap DownIMCCIM Cannabis0.0474 of 5 stars$2.38-3.6%N/A+3.4%$5.31M$51.39M-0.72340Gap DownBMRABiomerica0.1423 of 5 stars$0.31-1.2%N/A-76.8%$5.22M$5.51M-0.8260Gap DownAEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastPPBTPurple Biotech1.6642 of 5 stars$3.88+1.3%$33.00+750.5%N/A$5.16MN/A-0.4720BNOXBionomics2.517 of 5 stars$0.29-12.3%$8.00+2,707.0%-81.3%$5.03M$10,000.000.00N/AUPXIUpexi2.3417 of 5 stars$4.77-2.7%$25.00+424.1%-79.2%$4.98M$83.98M0.00130Earnings ReportPositive NewsGap Down Related Companies and Tools Related Companies GTBP Alternatives HOTH Alternatives CANF Alternatives ELAB Alternatives IMCC Alternatives BMRA Alternatives AEZS Alternatives PPBT Alternatives BNOX Alternatives UPXI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERNA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
